Palatin Technologies, Inc. (NYSE:PTN) Q4 2021 Earnings Conference Call September 29, 2021 11:00 AM ET Company Participants Carl Spana - President & CEO Steve Wills - EVP, CFO & COO Conference Call Participants Joe Pantginis - H.C. Wainwright John Newman - Canaccord Michael Higgins - Ladenburg Thalmann Operator Hello, ladies and gentlemen, and welcome to Palatin’s Fourth Quarter Fiscal Yearend 2021 Operating Results Conference Call. As a reminder, this conference is being recorded. Before we beginning our re ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10 - K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number: 001-15543 PALATIN TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 95-4078884 (State or othe ...

Palatin Technologies, Inc. (NYSE:PTN) Q3 2021 Earnings Conference Call May 17, 2021 11:00 AM ET Company Participants Carl Spana – President and Chief Executive Officer Steve Wills – Executive Vice President, Chief Financial Officer and Chief Operating Officer Conference Call Participants John Newman – Canaccord Joe Pantginis – H.C. Wainwright Michael Higgins – Ladenburg Thalmann Operator Good day, ladies and gentlemen, and welcome to the Palatin’s Third Quarter Fiscal Year 2021 Operating Results Conference ...

Revenue and Expenses - For the three and nine months ended March 31, 2021, product revenue was $88,741 and $(363,790) respectively, with no contract and license revenue recognized compared to $117,989 for the same period in 2020[127] - Research and development expenses were $2,509,490 and $9,444,759 for the three and nine months ended March 31, 2021, showing a decrease from $3,641,250 and $10,026,363 in the same periods of 2020[128] - Selling, general and administrative expenses increased to $4,010,055 and $11,386,574 for the three and nine months ended March 31, 2021, compared to $2,072,032 and $6,308,567 for the same periods in 2020[133] - A gain of $1,623,795 was recorded for the nine months ended March 31, 2021, due to the Vyleesi Termination Agreement[134] - Net cash used in operating activities was $14,111,599 for the nine months ended March 31, 2021, compared to cash provided of $47,402,881 for the same period in 2020[139] Cash Position and Liabilities - As of March 31, 2021, cash and cash equivalents were $68,641,312, with current liabilities of $10,036,841[141] - Existing capital resources are expected to be adequate to fund operations for at least twelve months, but additional funding will be needed for clinical trials and regulatory submissions[143] Strategic Focus and Development - The company is focusing on maximizing revenue from Vyleesi by marketing it in the U.S. and seeking additional licensees[131] - New product development activities are centered on peptides targeting inflammatory and autoimmune diseases, with potential applications in various conditions[121] - The company aims to enter strategic alliances with pharmaceutical companies to facilitate the development and commercialization of its product candidates[131] - The company plans to utilize existing capital resources for general corporate purposes, including marketing and distribution capabilities for Vyleesi in the U.S. and development of peptide programs[142] Future Outlook and Risks - Significant expenses are anticipated as the company develops marketing and distribution capabilities for Vyleesi, which will adversely affect stockholders' equity, total assets, and working capital[144] - There have been no material changes to the company's contractual obligations outside the ordinary course of business[146] - The company does not have any off-balance sheet arrangements[145] - Smaller reporting companies are not required to provide quantitative and qualitative disclosures about market risk[147]

Palatin Technologies, Inc. (NYSE:PTN) Q2 2021 Earnings Conference Call February 17, 2021 11:00 AM ET Company Participants Carl Spana – President and Chief Executive Officer Steve Wills – Executive Vice President, Chief Financial Officer and Chief Operating Officer Conference Call Participants John Newman – Canaccord Michael Higgins – Ladenburg Thalmann Operator Good day, ladies and gentlemen, and welcome to the Palatin Technologies' Second Quarter Fiscal Year 2021 Operating Results Conference Call. As a rem ...

Revenue and Financial Performance - For the six months ended December 31, 2020, the company recognized $(452,531) in product revenue, a decrease from $117,989 in the same period of 2019 due to regaining all North American rights to Vyleesi[150]. - Net cash used in operating activities was $10,607,131 for the six months ended December 31, 2020, a significant decrease from cash provided by operating activities of $49,914,993 in the same period of 2019[162]. - The company recorded a gain of $1,623,795 for the six months ended December 31, 2020, due to the Vyleesi Termination Agreement[158]. Research and Development - Research and development expenses increased to $6,935,269 for the six months ended December 31, 2020, compared to $6,385,113 for the same period in 2019, primarily due to increased spending on MCr programs[151]. - Cumulative spending on the Vyleesi program reached approximately $311,900,000, while spending on all other programs totaled approximately $161,100,000 as of December 31, 2020[154]. - The company is focusing on developing peptides that target MC1r and other melanocortin receptors for treating inflammatory and autoimmune diseases[143]. - The company is developing potential NPR candidate drugs to treat cardiovascular and fibrotic diseases[144]. Expenses and Liabilities - Selling, general and administrative expenses rose to $7,376,519 for the six months ended December 31, 2020, compared to $4,236,535 for the same period in 2019, driven by increased selling expenses related to Vyleesi[156]. - Significant expenses are anticipated for the development of marketing and distribution capabilities for Vylessi and other product candidates, adversely affecting stockholders' equity and working capital[167]. - Total contractual obligations as of December 31, 2020, amounted to $13,598,447, with current obligations of $1,328,657[170]. - Inventory purchase commitments total $12,344,200, with current commitments of $1,010,250[170]. Cash Flow and Funding - Net cash used in financing activities for the three months ended December 31, 2020, was $89,029, compared to $1,903,055 for the six months ended December 31, 2019[164]. - As of December 31, 2020, cash and cash equivalents were $72,156,110, with current liabilities of $7,249,643[164]. - The company has incurred cumulative negative cash flows from operations since inception and expects to continue substantial expenditures for marketing and distribution of Vylessi[164]. - The company plans to utilize existing capital resources for general corporate purposes and the development of various product programs[165]. - Additional funding will be required to complete clinical trials for other product candidates and regulatory submissions, with potential impacts from the COVID-19 pandemic[166]. - The company believes existing capital resources will be adequate to fund operations for at least twelve months from the date of the financial statements[166]. - There are no off-balance sheet arrangements reported[168]. Strategic Initiatives - The company aims to maximize revenue from Vyleesi by marketing it in the U.S. and seeking additional licensees in other regions[148]. - The company has entered into strategic alliances to facilitate the development and commercialization of its product candidates[148].

Palatin Technologies, Inc. (NYSE:PTN) Q1 2021 Earnings Conference Call November 17, 2020 11:00 AM ET Company Participants Carl Spana - President and Chief Executive Officer Steve Wills - Executive Vice President, Chief Financial Officer and Chief Operating Officer Conference Call Participants John Newman - Canaccord Joe Pantginis - H.C. Wainwright Edward Marks - Ladenburg Thalmann Operator Good day, ladies and gentlemen, and welcome to the Palatin Technologies First Quarter Fiscal Year 2021 Operating Result ...

Palatin Technologies, Inc. (NYSE:PTN) Q4 2020 Results Conference Call September 28, 2020 11:00 AM ET Company Participants Carl Spana - President & CEO Steve Wills - EVP, CFO, & COO Conference Call Participants John Newman - Canaccord Joseph Pantginis - H.C. Wainwright & Co Edward Marks - Ladenburg Thalmann Operator Good day, ladies and gentlemen, and welcome to the Palatin Technologies Fourth Quarter and Fiscal Year-end 2020 Operating Results Conference Call. As a reminder, this conference is being recorded ...

Palatin Technologies, Inc. (NYSE:PTN) Q3 2020 Earnings Conference Call May 12, 2020 11:00 AM ET Company Participants Carl Spana - Co-Founder, President, CEO & Director Stephen Wills - CFO, COO, EVP, Treasurer & Secretary Conference Call Participants John Newman - Canaccord Genuity Joseph Pantginis - H.C. Wainwright & Co. Michael Higgins - Ladenburg Thalmann & Co. Operator Good day, ladies and gentlemen, and welcome to the Palatin Technologies Third Quarter Fiscal Year 2020 Operating Results Conference Call. ...

Palatin Technologies, Inc. (NYSE:PTN) Q2 2020 Earnings Conference Call February 11, 2020 11:00 AM ET Corporate Participants Carl Spana - President and Chief Executive Officer Steve Willis - Chief Financial Officer Conference Call participants John Newman - Cowen Joe Pantginis - HC Wainwright Michael Higgins - Ladenburg Operator Good morning, ladies and gentlemen, and welcome to the Palatin Technologies Second Quarter Fiscal Year 2020 Operating Results Conference Call. As a reminder, this conference is being ...